SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism
Paris, Dijon (France) – April 27th,2023 - Exeliom Biosciences, a clinical-stage biotechnology company, and SATT Paris-Saclay, the Technology Transfer Accelerator Office of one of the world’s leading innovation clusters, announced today the signature of a license option agreement to develop a new drug candidate using a recombinant protein that mimics a natural enzyme totarget a specific pathway of the tryptophan metabolism.
Tryptophan is an amino-acid metabolized bymany bacteria in the human gut microbiome, thus playing a key role in our health. The products of this Tryptophan metabolism are known to be highly involved in a series of key biological processes including neurotransmission, inflammation and immune responses. Modulating the Tryptophan metabolism is seen as a promising therapeutic target to improve the lives of patients in a number of therapeutics areas.
SATT Paris-Saclay and Exeliom Biosciences are working in partnership with INRAE (France National Research Institute for Agriculture, Food, and Environment), a French leading academic institute, to develop a promising effector as new recombinant protein candidate to modulate the Tryptophan metabolism.
SATT Paris-Saclay very much looks forward to this partnership with Exeliom Biosciences and INRAe,” said Stéphane Gobron, Project Manager at SATT Paris-Saclay. “Exeliom Biosciences shares our vision of supporting academic research to develop novel high potential drug candidates.”
“We continue to invest in promising new microbiome-derived technologies that will change the way patients are treated,” said Benjamin Hadida, CEO and co-founder of Exeliom Biosciences. “This is part of our external innovation strategy that we have built over the years by nurturing strong historical partnerships with transfer organizations such as SATT Paris-Saclay and leading research institutes such as INRAE.”
About Exeliom Biosciences
Exeliom Biosciences,is a clinical-stage biopharmaceutical company specialized in the development of microbiome-based products with a mission to bring innovation to the pharmaceutical treatment of inflammatory bowel diseases and cancer. Its lead asset, EXL01, a rationally selected, oral live biotherapeutic product is in clinical development for the treatment of Crohn’s disease (https://clinicaltrials.gov/ct2/show/NCT05542355).
The Company was founded in 2016 in Paris and Dijon (France) by a renowned scientific team consisting of Prof. Harry Sokol (Professor of Gastroenterology, Saint Antoine Hospital in Paris), Dr. Philippe Langella (Research Director at INRAE) and Prof. Patrick Gervais (Professor of Process Engineering at AgroSup).
Additional information about Exeliom Biosciences at www.exeliombio.com
About SATT Paris-Saclay
From innovating concepts to practical applications, SATT Paris-Saclay (Technology TransferAccelerator Office) invests in disrupting technologies coming out of its territory’s research labs to accelerate their level of technological maturity and secure their entry into the markets. As a Technology Transfer Office for Université Paris-Saclay, CNRS and Institut Polytechnique de Paris, SATT generates business competitivity and creates a strong dynamic around deeptech innovations, boosting competitivity. SATT’s experts support researchers before project funding, to define the most appropriate industrial transfer strategy. Most demanded services include market opportunity study or IP portfolio analysis. SATT offers services dedicated to further industrial strategies of open-innovation and technological scouting. It also addresses companies who wish to exploit an innovation already funded by SATT or engage in specific developments with a lab supported by funds from SATT.
For more information, visit the organization’s website at www.satt-paris-saclay.fr/en/home.
INRAE is France's new National Research Institute for Agriculture, Food and Environment, created on January 1, 2020. It was formed by the merger of INRA, the National Institute for Agricultural Research, and IRSTEA, the National Research Institute of Science and Technology for the Environment and Agriculture. As the world's top institute for research on agriculture, food, and the environment, INRAE will help address these concerns. It will use research, innovation, and support for public policies as tools to guide the emergence of sustainable agricultural and food production systems. The institute aims to carry out science dedicated to life, humans, and the Earth that uncovers solutions to our most pressing concerns.
For more information, visit the organization’s website at https://www.inrae.fr/en.